Philips Dynamic Coronary Roadmap Software Evaluated for Image-Guided Navigation in PCI

May 16, 2023—Royal Philips announced late-breaking data from the largest randomized controlled multicenter clinical trial to investigate the ability of the company’s Dynamic Coronary Roadmap (DCR) software to reduce the total iodinated contrast media volumes administered during percutaneous coronary intervention (PCI) procedures, compared to PCI performed without DCR guidance.

DCR4Contrast, the Dynamic Coronary Roadmap for Contrast Reduction trial, was conducted from November 2019 to February 2023 across hospitals in the United States, Europe, and Israel.

As summarized by Philips, the multicenter, prospective, unblinded, stratified, 1:1 randomized controlled trial enrolled 371 patients who were randomized and stratified within both ad hoc and planned PCI, according to the number of vessels to be treated.

Patients in the DCR group underwent PCI procedures where DCR was used to guide coronary wires, balloons, stents, and other PCI diagnostic or therapeutic devices. Patients assigned to the control group underwent PCI without DCR support, following the current standard of care.

According to the company, the study found that the DCR reduced the total iodine contrast volume per procedure on average by 28.8% (95% CI, 18.9-38.2%). Also, DCR reduced the number of angiograms per procedure on average by three runs based on a procedure with an average of 11 runs, a 26.3% reduction (95% CI, 16.8-35.1%).

Results from DCR4Contrast were presented by Professor Javier Escaned, MD, in a late-breaking session at the annual EuroPCR course held May 16-19 in Paris, France. Additionally, the findings will be presented on May 18 by Professor John C. Messenger, MD, at the Society for Cardiovascular Angiography & Interventions’ SCAI 2023 Scientific Sessions, held May 18-20 in Phoenix, Arizona.

“Enabling physicians to decrease contrast administration during procedures with tools like DCR could make a significant contribution to both the safety and quality of PCI,” commented Prof. Escaned in Philips’ press release. “This is important at a time that PCI is growingly used in patients with a complex clinical or anatomical profile.” Prof. Escaned is Head of the Interventional Cardiology Section at Hospital Clinico San Carlos in Madrid Spain.

Prof. Messenger stated in the press release, “These results are very exciting. They confirm that Philips Dynamic Coronary Roadmap can be applied to all PCIs and has the potential to increase overall PCI safety by mitigating one of the few preventable contributors (iodinated contrast media use) to contrast-induced acute kidney injury following PCI.” Prof. Messenger is with the University of Colorado School of Medicine and is Director of the Cardiac Catheterization Laboratories and Cardiovascular ICU at the University of Colorado Hospital in Aurora, Colorado. The abstract of Prof. Messenger’s SCAI presentation will be posted on the meeting’s website here.

Philips stated that its DCR software is a real-time visualization innovation that removes the need for additional contrast media injections by overlaying the angiogram onto real-time motion-compensated two-dimensional fluoroscopic imaging to provide interventionalists with continuous visual feedback on the positioning of guidewires and catheters. The technology is complemented by Philips IntraSight precision guidance system that streamlines lesion assessment, simplifies vessel sizing, enables precise therapy delivery, and helps reduce contrast volumes, noted the company.